Drugs that contain Mitapivat Sulfate

1. List of Pyrukynd drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8785450 AGIOS PHARMS INC Therapeutic compounds and compositions
Feb, 2031

(8 years from now)

US11254652 AGIOS PHARMS INC Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
Nov, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682080 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(9 years from now)

US9980961 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(9 years from now)

US10632114 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(9 years from now)

US9193701 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
Oct, 2032

(9 years from now)

US11234976 AGIOS PHARMS INC Methods of using pyruvate kinase activators
Oct, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 17, 2027

NCE-1 date: February, 2026

Market Authorisation Date: 17 February, 2022

Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency by administering a daily dose of 10mg to 100mg

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic